Hypothesizing the end of traditional pharma hypothesizing, with Berg's Niven Narain

If the innovative approach being championed by Boston-based biopharma company Berg delivers to patients what it promises to, then it could spell the end for a number of features which characterize pharma today.

The chemical libraries and hypotheses of drug discovery, the trial-and-error prescribing of drugs for patients and the current state whereby rhetoric around precision medicine is more prevalent than treatments, will be consigned to history if Niven Narain, the chief executive of Berg, is correct in his predictions.

Founded in 2006, forging partnerships largely with academia, governments and research bodies, and under private ownership, the company has quietly gone about building a unique artificial intelligence (AI) based platform which puts patient needs at the center of research.